USPTO Examiner MAEWALL SNIGDHA - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18736363NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSJune 2024April 2025Allow1010NoNo
186555714,4'-[(2-HYDROXYPROPANE-1,3-DIYL)BIS(OXY)]DIBENZALDEHYDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)May 2024October 2024Allow601NoNo
18651753PEST CONTROL SPRAYMay 2024February 2025Allow1010NoNo
18419590METHOD FOR SUPPORTING MEMORY FUNCTION AND/OR COGNITIVE FUNCTIONJanuary 2024December 2024Allow1110NoNo
184000794,4'-[(2-HYDROXYPROPANE-1,3-DIYL)BIS(OXY)]DIBENZALDEHYDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023November 2024Abandon1011NoNo
18390158LEAVE-ON ORAL CARE COMPOSITIONSDecember 2023May 2025Allow1720NoNo
18516466INFUSION DOSAGE FORM OF NOREPINEPHRINENovember 2023September 2024Allow1010NoNo
18514738HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOFNovember 2023October 2024Allow1110NoNo
18506633FULVESTRANT FORMULATIONSNovember 2023December 2024Abandon1310NoNo
18498468Oral Care Compositions Comprising Tin IonsOctober 2023March 2025Allow1620NoNo
18498485Dentifrice Compositions Comprising Tin IonsOctober 2023March 2025Allow1620NoNo
18485516Methods and Compositions for Treating DiabetesOctober 2023February 2025Abandon1610NoNo
18244377ANTIMICROBIAL COMPOSITIONSSeptember 2023March 2025Allow1820NoNo
182396171,3-BIS(NAPHTHALEN-2-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)August 2023November 2023Allow300NoNo
18224348ANTIMICROBIAL COMPOSITIONS INCLUDING COPPER(I) SALTS AND ADDITIVESJuly 2023April 2024Allow921YesNo
18340177TOPICAL ANTIVIRAL COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS OF USING THE SAMEJune 2023April 2025Allow2210NoYes
18210514NON-THERAPEUTIC METHODS FOR ALLEVIATING OR REDUCING STRESS SYMPTOMS OF RUMINANTSJune 2023April 2025Allow2220NoNo
18207222Feral Hog ToxicantJune 2023February 2024Allow800NoNo
18205995DELIVERY SYSTEMJune 2023April 2025Allow2320YesYes
18323864NATURAL TOOTH POWDER TABLETSMay 2023July 2024Abandon1410NoNo
18308260INTRANASAL AND TRANSDERMAL ADMINISTRATION OF KAPPA-OPIOID-RECEPTOR AGONISTS: SALVINORIN A FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERSApril 2023August 2024Abandon1510NoNo
18136808INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESSApril 2023May 2024Allow1310NoNo
18136298Liposomal Compounds and Methods of Use ThereofApril 2023January 2024Allow910NoNo
18136306TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONSApril 2023July 2024Allow1520NoNo
18194540LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSMarch 2023March 2024Allow1220NoNo
18193328PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USEMarch 2023July 2024Abandon1610NoNo
18124897STABILIZED MENTHOL AND OTHER VOLATILE COMPOUND COMPOSITIONS AND METHODSMarch 2023February 2024Allow1110NoNo
18110654LIPID COMPOSITIONSFebruary 2023February 2024Allow1210NoNo
18110373BONE GRAFT COMPOSITION AND PREPARATION METHOD THEREFORFebruary 2023July 2024Abandon1710NoNo
18110791NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSFebruary 2023November 2024Abandon2120NoNo
18161988DRY POWDER FORMULATIONS FOR INHALATIONJanuary 2023March 2025Allow2540NoNo
18158583PESTICIDAL OR REPELLANT COMPOSITION AND METHOD OF USEJanuary 2023April 2024Abandon1530NoNo
18080474TRACE ELEMENT SOLUTIONDecember 2022September 2024Abandon2120NoNo
18076264Acetaminophen-Pregabalin Combinations And Methods Of Treating PainDecember 2022December 2023Allow1210NoNo
17962582COMPOSITIONS AND METHODS FOR REGULATING THE ENDOCANNABINOID SYSTEMOctober 2022August 2023Allow1010NoNo
17819726FULVESTRANT FORMULATIONSAugust 2022November 2023Abandon1510NoNo
17852486METHODS AND COMPOSITIONS FOR TREATING DIABETESJune 2022October 2023Abandon1610NoNo
17840332DIETARY NUTRIENT COMPOSITIONSJune 2022June 2024Allow2430YesNo
17785110PINK BOLLWORM CONTROL METHODJune 2022March 2025Allow3310NoNo
17825581Formulations of Magnesium Chloride to Treat Muscle Spasm, Strain and SprainMay 2022April 2025Allow3510NoNo
17749657METHODS FOR AMELIORATING INFUSION REACTIONSMay 2022November 2023Allow1810NoNo
17663586Novel 2,4-Dinitrophenol Formulations and Methods Using SameMay 2022September 2023Allow1610NoNo
17744275MATERIAL FOR DEMINERALIZING DENTIN COLLAGEN FIBRIL, PREPARATION METHOD AND APPLICATION THEREOFMay 2022January 2024Allow2030NoNo
17724019ORAL COMPOSITIONS AND METHODS OF USEApril 2022March 2024Allow2320NoNo
17715634DIETARY NUTRIENT COMPOSITIONSApril 2022February 2024Abandon2340NoNo
17712138ANTIMICROBIAL COMPOSITION AND SYSTEM FOR DELIVERING AN ANTIMICROBIAL COMPOSITIONApril 2022August 2024Allow2820YesNo
17685803Antimicrobial Compositions and Uses ThereofMarch 2022March 2023Allow1321NoNo
17682204ORAL CARE COMPOSITION AND DEVICES FORMED THEREWITHFebruary 2022March 2024Abandon2511NoNo
17584661Liver Activation Nanoemulsion and Toxin Excretion Enhancement MethodJanuary 2022July 2024Allow3020NoNo
17580224Oral Care Product and Methods of Use and Manufacture ThereofJanuary 2022January 2025Allow3640NoNo
17575489SUBLINGUAL EPINEPHRINE TABLETSJanuary 2022March 2024Allow2620NoNo
17570928COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATIONJanuary 2022October 2023Allow2110NoNo
17570635VACCINE ADJUVANT FORMULATIONJanuary 2022July 2023Allow1810NoNo
17566977Antimicrobial Products Containing Silver and Copper ParticlesDecember 2021August 2024Allow3220NoNo
17457460Pharmaceutical FormulationDecember 2021October 2023Allow2310NoNo
17528844Dimethyl Fumarate and Vaccination RegimensNovember 2021May 2023Abandon1810NoNo
17451292INFUSION DOSAGE FORM OF NOREPINEPHRINEOctober 2021September 2023Allow2220NoNo
17497810INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESSOctober 2021March 2023Allow1710NoNo
17472241Oral Care CompositionsSeptember 2021February 2025Allow4250NoNo
17433386DOSAGE PROJECTILE AND METHOD OF MANUFACTUREAugust 2021June 2025Allow4511NoNo
17410095ANTIVIRAL SMARTPHONE COVERAugust 2021December 2023Abandon2810NoNo
17408839Oral Care Compositions Comprising Tin IonsAugust 2021March 2025Allow4220NoNo
17408782Oral Care Compositions Comprising Tin IonsAugust 2021July 2023Allow2320NoNo
17408803Dentifrice Compositions Comprising Tin IonsAugust 2021July 2023Allow2320NoNo
17399160Method for supporting memory function and/or cognitive functionAugust 2021October 2023Allow2620NoNo
17391732ANTIMICROBIAL COATING COMPRISING CHALCOGENIDE NANO-PARTICLES CAPPED BY CHITOSANAugust 2021August 2023Allow2420NoNo
17389651Plant Extract Compositions and Methods of Making and Using the SameJuly 2021March 2025Abandon4410NoNo
17444033METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORSJuly 2021December 2023Allow2921NoNo
17377022METHODS OF CONTROLLING CROP PESTS USING AROMATIC AMIDE INSECT REPELLENTS, METHODS OF MAKING AROMATIC AMIDE INSECT REPELLENTS, AND NOVEL AROMATIC AMIDE INSECT REPELLENTSJuly 2021June 2024Allow3511NoNo
17423086FORMULATION FOR TREATING TOBACCO OR PSYCHOTROPE WITHDRAWAL SYMPTOMSJuly 2021February 2025Abandon4301NoNo
17365949DIETARY NUTRIENT COMPOSITIONSJuly 2021June 2024Allow3640NoNo
17358857GUMMIES CONTAINING FORMULATIONS WITH ENHANCED DELIVERY MATRIX, AND METHODS OF MAKING SAMEJune 2021November 2024Allow4110NoNo
17418418External CompositionJune 2021May 2025Allow4720YesNo
17357122LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSJune 2021March 2023Allow2120NoNo
17303926TREATMENT OF TOPICAL AND SYSTEMIC BACTERIAL INFECTIONSJune 2021May 2023Allow2410NoNo
17312423HYDROGEL FOR IN-VIVO DIRECTIONAL RELEASE OF MEDICATIONJune 2021December 2024Abandon4201NoNo
17342569BONE GRAFT COMPOSITION AND PREPARATION METHOD THEREFORJune 2021March 2023Abandon2110NoNo
17298184APPARATUS AND PROCESS FOR SECONDARY ENCAPSULATION OF SOLID INCLUSIONS USING THE ROTARY DIE PROCESSMay 2021February 2025Allow4520NoNo
17329587TOPICAL ANTIVIRAL COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS OF USING THE SAMEMay 2021March 2023Allow2210NoNo
17327241PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USEMay 2021April 2023Abandon2310NoNo
17314572FORTIFIED SANITIZING COMPOSITION HAVING ANTIMICROBIAL CHARACTERISTICSMay 2021September 2024Abandon4121NoNo
17314742DECONTAMINATION COMPOSITION AND PROCESSMay 2021January 2024Abandon3260NoNo
17286872ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ACID OR SILVER-BASED COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAMEApril 2021November 2024Allow4321NoYes
17286347LINKABLE POLYSILOXANES IN COSMETIC PRODUCTSApril 2021March 2024Abandon3501NoNo
17285628COMPOSITION FOR INCREASING SILICONE DEPOSITION ON KERATIN FIBERSApril 2021September 2024Allow4111NoNo
17224611Non-Toxic Larvicide Using Fennel Oil As ActiveApril 2021August 2023Abandon2911NoNo
17283053STABLE EMULSIONS OF BACTERIAL ANTIGENSApril 2021November 2024Allow4311NoNo
17222237METHOD FOR MANUFACTURING ACETAMINOPHEN PREPARATIONApril 2021June 2022Allow1521NoNo
17282594COMPOUNDS FOR USE IN PREVENTING OR TREATING ATHLETE OVERTRAININGApril 2021January 2025Allow4621NoNo
17278657PHOTODYNAMIC METHOD OF INHIBITING GROWTH OF A MICROBIAL PLANT PATHOGENMarch 2021June 2024Allow3920NoNo
17277813RODENTICIDE BAIT COMPOSITIONMarch 2021June 2024Allow3920NoNo
17200230LIPID COMPOSITIONSMarch 2021February 2023Abandon2310NoNo
17200252DIGESTIVE ENZYME COMPOSITION SUITABLE FOR ENTERAL ADMINISTRATIONMarch 2021July 2023Abandon2801NoNo
17194660Toothpaste for Delivering Allergens to Oral MucosaMarch 2021January 2024Allow3411NoNo
17273973EXTERNAL PREPARATION COMPRISING NON-LAMELLAR LIQUID CRYSTAL-FORMING LIPIDMarch 2021November 2024Allow4520YesNo
17269495METHOD TO PREVENT PROPAGATION OF IRREGULAR ELECTROMECHANICAL WAVES IN THE MYOCARDIUM BY CREATING LINES OF INCREASED TISSUE CONDUCTIVITYFebruary 2021June 2025Allow5121YesNo
17269502CYLINDRICAL MEMBER FOR IMPLANTATIONFebruary 2021August 2024Allow4210YesNo
17175525ANTIBIOTIC COMPOSITIONS FOR TREATING BACTERIAL INFECTIONSFebruary 2021September 2023Allow3120NoNo
17173971THERAPEUTIC OIL COMPOSITION FOR SHAVINGFebruary 2021March 2023Abandon2510NoNo
17160998STABILIZED MENTHOL AND OTHER VOLATILE COMPOUND COMPOSITIONS AND METHODSJanuary 2021November 2022Allow2240YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MAEWALL, SNIGDHA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
27
Examiner Affirmed
14
(51.9%)
Examiner Reversed
13
(48.1%)
Reversal Percentile
69.0%
Higher than average

What This Means

With a 48.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
115
Allowed After Appeal Filing
36
(31.3%)
Not Allowed After Appeal Filing
79
(68.7%)
Filing Benefit Percentile
45.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 31.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MAEWALL, SNIGDHA - Prosecution Strategy Guide

Executive Summary

Examiner MAEWALL, SNIGDHA works in Art Unit 1612 and has examined 1,060 patent applications in our dataset. With an allowance rate of 57.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner MAEWALL, SNIGDHA's allowance rate of 57.1% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MAEWALL, SNIGDHA receive 2.30 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MAEWALL, SNIGDHA is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +8.2% benefit to allowance rate for applications examined by MAEWALL, SNIGDHA. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.0% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 112.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 72.4% of appeals filed. This is in the 56% percentile among all examiners. Of these withdrawals, 59.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.9% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 46% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.